

VISION To achieve value driven leadership in to achieve value uriven requesting in Indian Health Care Industry and beyond. Quality that is infinite Service that cares Hardwork that endures

15th May, 2019

The Corporate Relationship Department	National Stock Exchange of India Limited
BSE Limited	Exchange Plaza,
Phiroze Jeejeebhoy Towers,	Bandra Kurla Complex,
Dalal Street,	Bandra East,
Mumbai 400 001.	Mumbai 400 051.
Scrip Code: 539523	Scrip Symbol: ALKEM

Dear Sirs,

Sub: Update on US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA

In furtherance to the intimation, captioned "US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA" dated 6th February, 2019 and 22nd March, 2019, this is to inform you that the Company has received a letter from the US FDA classifying the inspection conducted at its St. Louis facility as Official Action Indicated (OAI).

St. Louis facility contributes about 2% of the Company's total US revenues or about 0.5% of the Company's consolidated revenues. The Company believes that this classification will not have any significant impact on existing supplies or the existing revenues from the operations of this facility.

The Company shall continue to work closely with US FDA to close out all the observations associated with this inspection.

Kindly take the same on record.

Sincerely, For Alkem Laboratories Limited

Divya Mewani Sr. GM – Legal and Asst. Company Secretary